Key Takeaway: Cognition Therapeutics has reported positive results from its Phase 2 SHINE trial, demonstrating consistent improvements in cognitive outcomes for patients with mild-to-moderate Alzheimer's disease. The trial evaluated the efficacy of once-daily oral CT1812, which appears to be a promising treatment option. These findings may have significant implications for Alzheimer's therapy.
Price reaction · baseline $2.37 (2024-07-26 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close
-43.9%
day 1
-53.6%
day 3 · peak
-62%
Market Sentiment Analysis
POSITIVE FACTORS
Consistent improvement in cognitive outcomes observed.
Successful proof-of-concept in Phase 2 trial.
Once-daily oral CT1812 shows promise for Alzheimer's patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
Frequently Asked Questions
What is the SHINE trial?
The SHINE trial is a Phase 2 study evaluating CT1812 for Alzheimer's disease.
What were the results of the Phase 2 trial?
The trial demonstrated consistent improvements in cognitive outcomes for patients.
How often is CT1812 administered?
CT1812 is administered once daily in oral form.
Who were the participants in the trial?
Participants included patients with mild-to-moderate Alzheimer's disease.